Nasdaq suspends Windtree (WINT): -80% in 24 hours, moving to OTC and BNB strategy in jeopardy

Related

CoreWeave stock falls 15.25% to $65.945, with daily RSI at 29.28

CoreWeave stock has a bearish daily setup, and the...

Senate stalls bill over power-grid costs for the US digital economy

The Ratepayer Protection Act failed to advance in the...

France’s stablecoin tax could push traders offshore, Chainalysis CEO warns

France’s proposed stablecoin tax would apply its 31.4% capital...

Share

The suspension from Nasdaq for Windtree Therapeutics (ticker WINT), due to non-compliance with listing requirements and accompanied by an intraday collapse of –80%, has sparked strong fears among investors and raised questions about the recent initiative of treasury in BNB (initial commitment of $60 million with potential up to $200 million), indicating an already fragile financial balance.

According to the collected data, the stock went from about $0.48 before the notice to $0.11 at the close on August 21, 2025, confirming the very substantial intraday loss. Industry analysts monitoring small-cap biotech companies note that similar situations typically lead to a compression of capitalization and a significant reduction in liquidity in the first weeks following the delisting.